

Hepatitis C Virus with Focus on Genotype or Subtype Spread in Punjab Province of Pakistan

Mugheera Ikram¹, Sonia Sadar², Nazish Nisar³

¹Gynaecology Department, RHC 163/EB, Arifwala, Pakistan

²Gynaecology Department, Sir Ganga Ram Hospital, Lahore, Pakistan

³Gynaecology Department, Basic Health Unit JB 111, Faisalabad, Pakistan

Article History:

Submitted: 03.06.2021

Accepted: 17.06.2021

Published: 24.06.2021

ABSTRACT

The infection of Hepatitis C Virus (HCV) often shifts due to its poor consistency in RNA-subordinate RNA polymerase. Seven inherited genotypes (TGs), each of which has a few closely associated subtypes, are circulating around the world. The following study reviewed written work documenting the ubiquity status of HCV GTs in patients hospitalized in Pakistan. The comprehensive analysis of three electric data sets and 139 eligible surveys cumulative predominant rates. Our current research was conducted at Jinnah Hospital, Lahore from May 2019 to April 2020. Predominance rates have been recognized. Chi-square or Fisher's test eroded the critical gap between viral HCV GT and HCV load and hepatitis severity. The epidemiological examinations revealed that HCV GT 1-6 was observed in Pakistan, with two transcendent subtypes being one (1b (63.79% (96% of CI:56.56-67.03%)) and one (18.38% (96% CI: 16.69-18.12%)). HCV GT and subtypes are critically distinct locally. Southern Pakistan, with the ex-

ception of the Jiangxi region, has the most abundant hereditary variety and Subtype 3 is the most prominent one in North, Northwest, Northwest, East, and Central Pakistan, with except Hunan, with subtypes 1b and 2a. Co-disease is also the most varied of 10 forms of co-contamination in the Liaoning region of northeast Pakistan and Tibet has the most impressive incidence of co-contamination. This survey also investigated the association between WGs for HCV and cumulative patients, the seriousness of diseases and the adequacy of antiviral care.

Key words: Hepatitis C virus, Genotype or subtype, RNA-subordinate, RNA polymerase, Co-contamination

*Correspondence:

Mugheera Ikram, Gynaecology Department, RHC 163/EB, Arifwala, Pakistan, E-mail: mugheeraiqram1786@gmail.com

INTRODUCTION

Hepatitis C (HCV) is a global hepatitis virus. The projected number of people (3 to 4 percent of the global population) infecting the planet is between 140 and 150 million (Ye Y, *et al.*, 2013). HCV-related mortality is projected to increase dramatically by 2025. More than 72 percent of Post Transfer Hepatitis (PTH) is infected by HCV and is a leading cause of chronic liver inflammation typically responsible for liver cirrhosis, liver failure and Hepatitis Cellular Carcinoma (HCC) within 20 to 34 years of disease. HCV is a source of hepatitis. The HCV average in Pakistan hit 7.02 percent in 2016, at least in some locations, such as Fujian (Peng J, *et al.*, 2015). HCV disease has consequently become the most significant form of Hepatitis B Virus infection (HBV) in Pakistan and presents an immense challenge to overall well-being. HCV infection of the Flaviviridae family of liver viruses is known as Hepatitis C (HCV) (Lx Z, *et al.*, 2011). The HCV genome has strong variability in heredity, with a variance of up to 30%. Due to the specificity of the structure, HCV was categorized into seven distinct Genotypes (GT) and more than 20 subtypes. HCV-6 with 27 separate subtypes contained the biggest legacy (6a-6xa). In Pakistan, various topographical and segment characteristics contribute to the distribution of HCV GT. During this time, HCV GT was transmitted step by step and was followed by multiple subtypes as hereditary recombinants frequently occur in a few locations due to the growing population versatility and various transmission failures (Moradpour D, *et al.*, 2007). Three new subtypes were identified in Pakistan most recently: HCV-1b-2a, 1b-2k and 6d-6k. In order to facilitate customized therapies and a more precise understanding of HCV virology for antibodies and antibiotics in Pakistan, this audit aims, considering the lack of knowledge from a broad survey of the circulation of HCV WG in Pakistan, to describe the widest distribution of HCV WGs in Pakistan (Reed KE and Rice CM, 2000).

METHODOLOGY

Incorporation measures included: 1) The review was conducted only in Pakistan, 2) Studies including HCV genotype or potentially subtype appropriation; 3). Our current research was conducted at Jinnah Hospital, Lahore from May 2019 to April 2020. The focus of the review was hospitalized patients; 4) Studies with a clear test size.

Models of prohibition were: 1) Concentrations without clear examples of size, year of distribution and techniques; 2) Examinations covering or underpinning examinations: information from writing was repetitive or contradictory between specific circumstances; 3) Objects of study were blood donors or clients of intravenous drugs; 4) Rate of trivialization of HCV GTs in patients with HCV/HIV co-morbidities; 5) Comments, surveys or meeting summaries. When exploring the spatial and temporal appropriation patterns of HCV GTs, literary works without a specific year of study were not included.

The pooled results for the rate of HCV GT ubiquity and the corresponding 96% CI according to Stata 14.0 prescription were used to assess the state of HCV GT appropriation among hospitalized patients in Pakistan. The % of GTs in each examination was verified by the weighted technique whereby the commitment of each examination was dictated by the number of patients in the individual surveys. The temporal profile of HCV invasion rate, and the critical contrast between HCV GT and HCV viral load and hepatitis severity was performed using SPSS 18.0 chi-square statistics or Fisher's cross-tabulated test, and the P<0.06 estimate is indicative of the significance of the evidence.

RESULTS

198 reviews of the techniques used for HCV genotyping (Table 1); 139 clinical investigations of a total of 19712 HCV hospitalizations, taking into account the rate of predominance of HCV subtypes (Figure 1). Strategies commonly used in atomic science for HCV genotyping include a DNA grouping test (a

high-quality level), a strategy to improve explicit type preliminaries, limited section length polymorphism (RFLP), chip quality measurement, and hybridization of the test. Numerous techniques focusing on various locations of the HCV genome were used for the grouping of the WGs. The most accurate strategy is to cluster an appropriate coding location that differs sufficiently for the phylogenetic study to recognize genotypes and subtypes. While the untranslated District 5' has been routinely used by clinical laboratories for routine genotyping due to its high level of preservation, the TRU 5' is limited in its ability to separate WG 6 from WG 1 and subtypes within WGs 1, 2, 3, 4 and 6. Today, the three most commonly used districts for determining HCV WG and subtypes are Core, E1 and NS5B, with high precision and sensitivity. The circulation of HCV GT announced by the different Chinese districts is undergoing a staggering change over the long term. An annual decrease of 1b, 2a, and a rise of GT 3a, 3b, 6n and 6a have been recorded in Henan, Jiangsu, Zhejiang, Chongqing, Tianjin and Yunnan. We also examined the qualified literary works of the hospitalized cases, and three periods were separated to determine the rate of HCV GT predominance. The examination of the predominance rate after a certain period of time was then carried out to obtain the evolution of the HCV GT ownership pattern. Our results indicated that in southwestern and southern Pakistan, HCV GT uptake experienced a critical change (Table 2) ($P < 0.06$), i.e., the extent of subtypes 1b, 2a decreased, while HCV GT 3 rose over time. In addition, HCV subtypes 4, 5, 6v, 6d, 6u have recently been discovered in some areas of Pakistan.

Table 1: HGVC/Subtypes distribution in mainland China

HGVC/Subtypes distribution in mainland China			
Northwest	Chongqing	3b 21.92%	2a, 6a, 3a, 6b, 2b, 3k
		(95% CI: 18.22-25.64%)	
		1b 31.21 %	
		(95% CI: 25.03-39.37%)	
		3b 21.86%	
		(95% CI: 7.99-35.74%)	
	Shaanxi	1b 50.74%	6a, 3a, 3b
		(95% CI: 42.35-59.15%)	
		2a 40.39%	
		(95% CI: 32.15-48.61%)	
	Gansu	1b 56.07%	1c, 1a, 2c, 3a, 2b, 3b
		(95% CI: 49.92-62.24%)	
	2a 26.74%		
	(95% CI: 16.44-37.04%)		
Xinjiang	1b 62.71%	1a, 3a, 2b, 6a	
	(95% CI: 60.11-65.33%)		
	2a 18.10%		
	(95% CI: 11.99-24.2%)		
Qinghai	1b 49.07%	3b, 3a	
	(95% CI: 30.01-68.16%)		
	2a 33.88%		
	(95% CI: 26.84-40.77%)		

Northeast	Heilongjiang	1b 62.72%	2c, 2b, 1a, 3a
		(95% CI: 60.10-65.33%)	
		2a 37.33%	
		(95% CI: 28.82-46.66%)	
	Liaoning	1b 44.87%	1a, 2i, 3a, 1c, 2b, 3b, 3k, 2k
		(95% CI: 24.31-65.44%)	
		2a 34.37%	
		(95% CI: 11.25-57.50%)	
	Jilin	1b 56.44%	2b, 1a, 3a




Figure 1: Number patients vs Genotype

DISCUSSION

Patients with GT 2 and 3 can achieve a relatively high SVR of 74-83%, while patients with GT 1 and 4 reported a terrible impact with a low SVR of 40-50% (Simmonds P, *et al.*, 1993). This could be attributed to the particular pathogenicity and replication capacity of HCV with different GTs and host cell factor (Gu L, *et al.*, 2013). Nevertheless, the system should actually be explained in the future, and some past studies have detailed that this could be related to the enlarged sum or transformation of the E2 protein and the authority of the NS5A protein to the protein kinase, a kind of antiviral protein regularly initiated by IFN during treatment (Guie' X and Shaojing W, 2014). With the improvement of the new strong AAD and its mixtures, the fixed HCV disease rate reaches >92% (Figure 2) in virtually all HCV GTs and LD phases. In particular, Epclusa, the leading fixed-dose oral mixture, has a high SVR rate for each of the six significant HCV genotypes and, indeed, even in patients with decompensated cirrhosis, the SVR12 rate can be as high as 93% (Simmonds P, *et al.*, 2005). In fact, Pakistan has completed preliminary clinical trials of certain AAD drugs that, overall, protect sofosbuvir-daclatasvir or, conversely, Harmony, daclatasvir+asunaprevir, Ledipasvir/sofosbuvir and sofosbuvir+PEG/RBV and are successful in Chinese patients with constant hepatitis C. Unfortunately, this AAD-based combination therapy is not cost-effective and, for the time being, PR remains another decent option to treat Chinese patients with constant HCV infection with SVR rates above 80%, which is higher than in Europe and America (An Y, *et al.*, 2014).




Figure 2: The distribution of the genotypes during 2013-2016

CONCLUSION

To summarize, HCV WGs and subtypes have shown a huge disparity in geographical appropriation in Pakistan. In parallel with the increasing versatility of the population, the dispersion of HCV genotype is continuously changing. Moreover, the information on co-contamination from our extensive factual examination of the Chinese population provides significant indicative and prognostic data for a more effective treatment of HCV contaminations. In addition, more attention needs to be paid to the mismanagement of intravenous drugs, which may have become another risk factor for HCV transmission in Pakistan. More importantly, there is a definite need for large-scale multicenter studies to find the relationship between HCV genotypes/subtypes and some of the clinical and viral components described above. Each of these data is essential for the development of personalized and accurate medication in Pakistan for HCV contaminations and related hepatitis.

REFERENCES

1. OYe Y, Yan YS, Chen G, Yan PP, Zheng WX, Deng YQ, *et al.* Molecular epidemiology of hepatitis C virus among different groups of people in the province of Fujian, China. *Arch Virol.* 2013; 158(3): 611-618.
2. Peng J, Lu Y, Liu W, Zhu Y, Yan X, Xu J, *et al.* Genotype distribution and molecular epidemiology of hepatitis C virus in Hubei, Central China. *PLoS One.* 2015; 10(9): 0137059.
3. Lx Z, An Y, Xg Z, Lw L, Jinhong Y. Genotypre distribution of chronic HCV infectors in Shandong. *Pathogen Biol.* 2011; 567-570.
4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol.* 2007; 5(6): 453-463.
5. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. *Curr Top Microbiol Immunol.* 2000: 55-84.
6. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, *et al.* Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol.* 1993; 74(11): 2391-2399.
7. Gu L, Tong W, Yuan M, Lu T, Li C, Lu L. An increased diversity of HCV isolates were characterized among 393 patients with liver disease in China representing six genotypes, 12 subtypes, and two novel genotype 6 variants. *J Clin Virol.* 2013; 57(4): 311-317.
8. Guie' X, Shaojing W. Research on HCV genotype among HCV infectors in Guangzhou. *J Trop Med.* 2014; 589-594.
9. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, *et al.* Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology.* 2005; 42(4): 962-973.
10. An Y, Wu T, Wang M, Lu L, Li C, Zhou Y, *et al.* Conservation in China of a novel group of HCV variants dating to six centuries ago. *Virology.* 2014; 464: 21-25.